Johnson & Johnson (JNJ)vsOncology Institute Inc (TOI)
JNJ
Johnson & Johnson
$270.00
-1.57%
HEALTHCARE · Cap: $632.29B
TOI
Oncology Institute Inc
$5.13
+5.56%
HEALTHCARE · Cap: $512.91M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 17843% more annual revenue ($97.93B vs $545.76M). JNJ leads profitability with a 21.5% profit margin vs -8.0%. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
TOI
Hold45
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for JNJ.
Margin of Safety
+22.9%
Fair Value
$3.40
Current Price
$5.13
$1.73 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Revenue surging 41.2% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Earnings declined 0.9%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -652.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : TOI
The strongest argument for TOI centers on Revenue Growth, Debt/Equity. Revenue growth of 41.2% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : TOI
The primary concerns for TOI are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while TOI is a hypergrowth play — different risk/reward profiles.
TOI carries more volatility with a beta of 0.42 — expect wider price swings.
TOI is growing revenue faster at 41.2% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 45/100), backed by strong 21.5% margins. TOI offers better value entry with a 22.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Oncology Institute Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Oncology Institute Inc (ticker: TOI) is a leading healthcare organization focused on revolutionizing cancer care through its extensive network of specialized clinics and innovative treatment methodologies. By harnessing advanced technologies and personalized care strategies, the company aims to significantly improve patient outcomes while emphasizing clinical trials and partnerships with premier research institutions. Positioned to capitalize on the growing demand for advanced cancer therapies, TOI benefits from a solid pipeline and a wealth of oncology expertise, presenting a compelling investment opportunity within the dynamic healthcare landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?